2 assets in Pregerminal Center Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Therapeutic assets addressing Pregerminal Center Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Lenalidomide Pregerminal Center Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	National Cancer Institute (NCI)	P2	CCC (53)
Pneumococcal Polyvalent Vaccine Pregerminal Center Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	National Cancer Institute (NCI)	P2	CCC (53)